SNSE RSI Chart
Last 7 days
-1.9%
Last 90 days
38.4%
Trailing 12 Months
-32.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 2.4M | 3.0M | 3.4M | 3.6M |
2022 | 1.0M | 1.3M | 1.5M | 1.8M |
2021 | 0 | 0 | 0 | 800.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 15, 2024 | celebi john | sold (taxes) | -4,653 | 0.79 | -5,891 | president and ceo |
Feb 15, 2024 | colgan erin | sold (taxes) | -2,865 | 0.79 | -3,627 | chief financial officer |
Feb 15, 2024 | van der horst edward | sold (taxes) | -2,245 | 0.79 | -2,843 | chief scientific officer |
Sep 11, 2023 | celebi john | bought | 425 | 0.85 | 500 | president and ceo |
Jul 31, 2023 | peyer james | back to issuer | -2,000,000 | 1.26 | -1,587,300 | - |
Jul 31, 2023 | cambrian biopharma inc | back to issuer | -2,000,000 | 1.26 | -1,587,300 | - |
Jul 10, 2023 | cambrian biopharma inc | acquired | - | - | 4,466 | - |
Jul 10, 2023 | peyer james | acquired | - | - | 4,466 | - |
Jul 10, 2023 | holmen bob | acquired | - | - | 4,466 | - |
Jul 10, 2023 | ringo william r | acquired | - | - | 4,466 | - |
Which funds bought or sold SNSE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 10, 2024 | Banque Cantonale Vaudoise | unchanged | - | 1,000 | 4,000 | -% |
Mar 14, 2024 | Leo Wealth, LLC | new | - | 10,273 | 10,273 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | unchanged | - | -61,955 | 396,966 | -% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | sold off | -100 | -2.00 | - | -% |
Feb 14, 2024 | Duquesne Family Office LLC | unchanged | - | -11,000 | 69,000 | -% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | -1,497 | 17,836 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | added | 0.02 | -9,793 | 62,826 | -% |
Feb 14, 2024 | Newtyn Management, LLC | reduced | -12.67 | -262,340 | 1,087,840 | 0.21% |
Feb 14, 2024 | TWO SIGMA ADVISERS, LP | reduced | -2.06 | -2,372 | 13,148 | -% |
Feb 14, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -33.18 | -16,487 | 26,500 | -% |
Unveiling Sensei Biotherapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Sensei Biotherapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.41 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.5B | 1.8B | -42.01 | 10.12 | ||||
BMRN | 17.2B | 2.4B | 102.31 | 7.09 | ||||
INCY | 11.9B | 3.7B | 20 | 3.23 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.82 | 15.75 | ||||
BBIO | 4.4B | - | -6.81 | 60.35 | ||||
AXSM | 3.3B | 270.6M | -13.62 | 12.04 | ||||
ARWR | 2.9B | 240.7M | -9.88 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.63 | 4.6 | ||||
NVAX | 557.0M | 983.7M | -1.02 | 0.57 | ||||
CRBP | 432.8M | 881.7K | -9.7 | 466.16 | ||||
INO | 225.3M | 4.9M | -1.67 | 46.29 | ||||
IBIO | 6.8M | 2.1M | -0.25 | 2.14 |
Sensei Biotherapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | -5.8% | 826 | 877 | 952 | 969 | 609 | 515 | 349 | 310 | 294 | 278 | 188 |
Operating Expenses | 5.2% | 8,142 | 7,737 | 10,177 | 11,008 | 13,048 | 13,941 | 10,712 | 12,487 | 9,413 | 10,316 | 9,784 |
S&GA Expenses | -6.9% | 3,649 | 3,919 | 5,393 | 5,804 | 5,703 | 4,751 | 4,319 | 5,032 | 3,457 | 3,873 | 3,886 |
Interest Expenses | -6.1% | 31.00 | 33.00 | 38.00 | 42.00 | -206 | 10.00 | 172 | 243 | 306 | 214 | 147 |
Net Income | -4.1% | -7,414 | -7,124 | -9,386 | -10,177 | -12,232 | -13,416 | -10,535 | -12,405 | -9,366 | -9,685 | -9,771 |
Net Income Margin | 17.6% | -9.41* | -11.42* | -14.85* | -18.98* | -27.25* | -29.74* | -32.51* | -39.42* | -45.99* | - | - |
Free Cashflow | -32.2% | -6,163 | -4,661 | -9,492 | -11,887 | -9,574 | -7,053 | -11,951 | -10,769 | -8,403 | -5,965 | -6,663 |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -8.9% | 74.00 | 82.00 | 90.00 | 108 | 118 | 129 | 138 | 150 | 153 | 161 | 168 | 174 | 21.00 |
Current Assets | -8.9% | 67.00 | 74.00 | 81.00 | 99.00 | 109 | 118 | 127 | 139 | 149 | 158 | 166 | 173 | 20.00 |
Cash Equivalents | 14.7% | 13.00 | 11.00 | 10.00 | 8.00 | 18.00 | 11.00 | 10.00 | 9.00 | 7.00 | 10.00 | 16.00 | 169 | 17.00 |
Net PPE | -10.3% | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 5.00 | 3.00 | 2.00 | 2.00 | 1.00 |
Liabilities | -11.1% | 9.00 | 11.00 | 10.00 | 13.00 | 15.00 | 15.00 | 12.00 | 15.00 | 7.00 | 6.00 | 5.00 | 3.00 | 6.00 |
Current Liabilities | -9.4% | 6.00 | 6.00 | 5.00 | 8.00 | 9.00 | 8.00 | 5.00 | 8.00 | 5.00 | 5.00 | 4.00 | 2.00 | 5.00 |
Shareholder's Equity | -8.6% | 65.00 | 71.00 | 79.00 | 95.00 | 103 | 114 | 126 | 135 | 147 | 155 | 163 | 171 | - |
Retained Earnings | -3.3% | -231 | -224 | -217 | -207 | -197 | -185 | -172 | -161 | -149 | -139 | -130 | -120 | -112 |
Additional Paid-In Capital | 0.4% | 297 | 296 | 297 | 304 | 302 | 301 | 299 | 298 | 296 | 295 | 293 | 292 | 56.00 |
Shares Outstanding | 0.1% | 25.00 | 25.00 | 27.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 25.00 | 19.00 | 2.00 |
Float | - | - | - | 19.00 | - | - | - | 36.00 | - | - | - | 204 | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -32.2% | -6,163 | -4,661 | -9,463 | -11,736 | -9,574 | -6,803 | -11,899 | -10,750 | -7,868 | -5,577 | -6,047 | -10,767 | -2,680 | -5,798 | -2,767 | -6,460 |
Share Based Compensation | 4.8% | 1,098 | 1,048 | 1,095 | 1,213 | 1,399 | 1,479 | 1,419 | 1,515 | 826 | 1,736 | 1,746 | 1,349 | 354 | 781 | 163 | 194 |
Cashflow From Investing | -0.6% | 8,262 | 8,312 | 19,526 | 2,312 | 16,043 | 8,517 | 13,196 | 12,193 | 5,612 | -482 | -147,761 | -487 | -316 | -836 | -199 | -52.00 |
Cashflow From Financing | 83.0% | -431 | -2,534 | -7,946 | -262 | -124 | - | - | 119 | -118 | -7.00 | -11.00 | 164,076 | 15,859 | 8,481 | 556 | 10,557 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 18,299 | $ 30,383 |
General and administrative | 18,765 | 19,805 |
Total operating expenses | 37,064 | 50,188 |
Loss from operations | (37,064) | (50,188) |
Other income (expense): | ||
Interest income | 3,624 | 1,783 |
Interest expense | (144) | (219) |
Loss on asset disposal | (302) | |
Other (expense) income, net | (215) | 36 |
Net loss | $ (34,101) | $ (48,588) |
Net loss per common share, basic | $ (1.22) | $ (1.58) |
Net loss per common share, diluted | $ (1.22) | $ (1.58) |
Weighted-average number of shares used in computing net loss per common share, basic | 27,952,857 | 30,703,295 |
Weighted-average number of shares used in computing net loss per common share, diluted | 27,952,857 | 30,703,295 |
Comprehensive loss: | ||
Net loss | $ (34,101) | $ (48,588) |
Other comprehensive items: | ||
Unrealized gain (loss) on marketable securities | 795 | (671) |
Total other comprehensive income (loss) | 795 | (671) |
Total comprehensive loss | $ (33,306) | $ (49,259) |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 13,011 | $ 17,795 |
Marketable securities | 52,746 | 89,321 |
Prepaid expenses | 1,168 | 1,129 |
Other current assets | 325 | 344 |
Total current assets | 67,250 | 108,589 |
Right of use assets - operating leases, net | 4,330 | 5,355 |
Right of use assets - financing leases, net | 1,543 | 2,319 |
Property and equipment, net | 1,165 | 2,049 |
Other non-current assets | 86 | 63 |
Total assets | 74,374 | 118,375 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 1,694 | 4,473 |
Compensation and employee benefits liabilities | 1,510 | 2,462 |
Operating lease liabilities, current | 1,567 | 1,251 |
Financing lease liabilities, current | 872 | 880 |
Total current liabilities | 5,643 | 9,066 |
Operating lease liabilities, non-current | 3,001 | 4,323 |
Financing lease liabilities, non-current | 768 | 1,579 |
Other non-current liabilities | 67 | |
Total liabilities | 9,479 | 14,968 |
Commitments and contingencies (Note 6) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value and 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; zero shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | ||
Common stock, $0.0001 par value and 250,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 25,030,188 and 30,764,160 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 3 | 3 |
Additional paid-in capital | 296,996 | 302,202 |
Accumulated deficit | (231,895) | (197,794) |
Accumulated other comprehensive loss | (209) | (1,004) |
Total stockholders' equity | 64,895 | 103,407 |
Total liabilities and stockholders' equity | $ 74,374 | $ 118,375 |